What is Exela Pharma Sciences?
Exela Pharma Sciences is an award-winning, integrated specialty pharmaceutical company headquartered in Lenoir, North Carolina. Established in 2005, the company specializes in the development and manufacturing of proprietary and generic sterile injectable products. Exela addresses critical needs within the healthcare sector by improving patient experiences and mitigating drug shortages. The company operates through two distinct business units: Finished Drug Products and Contract Development and Manufacturing Organization (CDMO), utilizing substantial cGMP sterile manufacturing capacity. Their dedication to stringent quality standards has solidified their reputation as a reliable partner in the pharmaceutical supply chain.
How much funding has Exela Pharma Sciences raised?
Exela Pharma Sciences has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Exela Pharma Sciences
PPP
Public-Private Partnership
What's next for Exela Pharma Sciences?
The recent major strategic investment, alongside the overall enterprise-level funding context, indicates Exela Pharma Sciences is poised for significant expansion and operational enhancement. This capital infusion is likely to fuel advancements in their sterile injectable product lines, bolster their CDMO capabilities, and potentially broaden their market reach. The company's focus on addressing drug shortages and improving patient outcomes positions them for continued growth and influence within the pharmaceutical industry, suggesting a trajectory towards scaling operations and solidifying their market leadership.
See full Exela Pharma Sciences company page
